2020 Fiscal Year Final Research Report
Effects of anti-bone resorptive drugs on growth and tooth development in young mice.
Project/Area Number |
18K09866
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 57070:Developmental dentistry-related
|
Research Institution | Showa University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
高見 正道 昭和大学, 歯学部, 教授 (80307058)
|
Project Period (FY) |
2018-04-01 – 2021-03-31
|
Keywords | 歯牙萌出 / 抗RANKL抗体 / ビスホスホネート / 破骨細胞 / 骨芽細胞 |
Outline of Final Research Achievements |
Anti-bone-resorptive drugs are used to treat children’s bone disease, however, the precise effects on tooth eruption are unknown. In the present study, we administrated an anti-RANKL antibody or zoledronate (a bisphosphonate) on 1-week-old mice to made osteoclast-suppressed model mice and analyzed the effect of anti-resorptive drugs on growth and tooth development in young mice. The anti-resorptive drugs decreased expression of immune cells in bone marrow in infants. Mice, which were continuously treated with zoledronate, showed delay of tooth eruption and decreased number of osteoblasts, and inhibited growth of jaw bone, cranial bone and limb after growth. These results suggest that anti-bone-resorptive drugs are affects tooth development in young patients.
|
Free Research Field |
歯科薬理学
|
Academic Significance and Societal Importance of the Research Achievements |
抗RANKL抗体(一般名デノスマブ)、およびゾレドロネートなどのビスホスホネート製剤は、成人の骨疾患の治療に高い効果を発揮する優れた骨吸収抑制薬である。骨吸収抑制薬は治療の必要性から小児の骨形成不全症やステロイド性骨粗鬆症などの治療に用いられているが、小児の成長に対する影響は未解明な部分が多い。 本研究では小児期の骨吸収抑制薬投与が成体にも影響を及ぼすことを明らかにした。これは骨吸収抑制薬を小児に投与する際に、免疫機能や成長を注意深く確認して投薬計画を調整する必要があることを示すものであり、治療後のQOL向上に大きく貢献する成果である。
|